RoboCT Secures $14M in Series B Funding to Propel Next-Generation Lower Limb Exoskeletons for Rehabilitation

We are excited to announce that 程天科技 RoboCT has successfully raised $14,000,000 in its latest funding round—a significant milestone that underscores the company’s innovative strength and promising future in rehabilitation technology. RoboCT, a pioneering leader in the field of lower limb exoskeletons, has developed a robust portfolio of five series of exoskeletons: UGO, Kid GO, GOGO, the Bedside Exoskeleton, and DEUS. Each series is meticulously engineered to address diverse rehabilitation needs, catering to patients ranging from children to adults, and to support various stages of recovery from mobility impairments. This latest capital injection will empower RoboCT to accelerate its research and development initiatives, ensuring that cutting-edge technologies are harnessed to push the boundaries of robotic rehabilitation. The funding is strategically allocated towards expanding the company’s product development pipeline, enhancing its manufacturing capabilities, and increasing market outreach. Investment in these key areas will not only boost production efficiency but also enable the acceleration of clinical trials and user-experience testing, ensuring that the highest standards of safety and efficacy are maintained. Furthermore, the additional resources will allow 程天科技 RoboCT to forge strategic partnerships with healthcare institutions and rehabilitation centers worldwide. This collaboration will further explore the integration of advanced technology into daily clinical practices, ultimately aiming to improve patient outcomes and quality of life. As RoboCT continues to lead the charge in revolutionizing rehabilitation through unparalleled engineering and thoughtful design, this funding milestone marks the beginning of an exciting chapter for the company, its partners, and the countless individuals who stand to benefit from these groundbreaking advancements in mobility assistance.